StockData
AC Immune SA logo

AC Immune SA (ACIU) stock

ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 13, 2026Score 3/30
$2.11+0.02 (+0.96%)

Close on Nov 17, 2026Market cap $214.68MP/E –Yield –

Earnings

AC Immune's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2025
CHF 1.30M
EPS, Q2 FY2025
-0.21 CHF
Latest guidance
Issued
Mar 13, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of AC Immune's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Mar 13, 2026before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the openCHF 1.30M–-0.21 CHFRelease
Q4 FY2024ended Dec 31, 2024Mar 13, 2025before the open–––Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open–––Release
Q4 FY2023ended Dec 31, 2023Mar 14, 2024before the open–––Release
Q2 FY2023ended Jun 30, 2023Aug 4, 2023before the open––-0.20 CHFRelease
Q4 FY2022ended Dec 31, 2022Apr 28, 2023before the open––-0.21 CHFRelease
Q3 FY2022ended Sep 30, 2022Oct 28, 2022before the open–––Release
Q2 FY2022ended Jun 30, 2022Jul 28, 2022before the open–––Release
Q4 FY2021ended Dec 31, 2021Mar 22, 2022before the open–––Release
Q3 FY2021ended Sep 30, 2021Nov 8, 2021before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

AC Immune's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total cash expenditurenon-GAAPFY202575 – 85–NewMar 13, 2025
total cash expenditurenon-GAAPFY202655 – 65–NewMar 13, 2026

Guidance history

Every forecast AC Immune put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 13, 2026total cash expenditureFY202655 – 65New
Mar 13, 2025total cash expenditureFY202575 – 85New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases AC Immune filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?